Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis | Zendy

Luca Richeldi | Zendy; Roland M. du Bois | Zendy; Ganesh Raghu | Zendy; Arata Azuma | Zendy; Kevin M. Brown | Zendy; Ulrich Costabel | Zendy; Vincent Cottin | Zendy; Kevin Flaherty | Zendy; David M. Hansell | Zendy; Yoshikazu Inoue | Zendy; Dong Soon Kim | Zendy; Martin Kolb | Zendy; Andrew G. Nicholson | Zendy; Paul W. Noble | Zendy; Moisés Selman | Zendy; Hiroyuki Taniguchi | Zendy; Michèle Brun | Zendy; Florence Le Maulf | Zendy; M Girard | Zendy; Susanne Stowasser | Zendy; Rozsa SchlenkerHerceg | Zendy; Bernd Disse | Zendy; Harold R. Collard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Author(s) -

Luca Richeldi,

Roland M. du Bois,

Ganesh Raghu,

Arata Azuma,

Kevin M. Brown,

Ulrich Costabel,

Vincent Cottin,

Kevin Flaherty,

David M. Hansell,

Yoshikazu Inoue,

Dong Soon Kim,

Martin Kolb,

Andrew G. Nicholson,

Paul W. Noble,

Moisés Selman,

Hiroyuki Taniguchi,

Michèle Brun,

Florence Le Maulf,

M Girard,

Susanne Stowasser,

Rozsa SchlenkerHerceg,

Bernd Disse,

Harold R. Collard

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1402584

Subject(s) - nintedanib , medicine , idiopathic pulmonary fibrosis , placebo , exacerbation , vital capacity , clinical endpoint , gastroenterology , clinical trial , pathology , lung , lung function , alternative medicine , diffusing capacity

Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research